<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations and diagnosis of obesity hypoventilation syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations and diagnosis of obesity hypoventilation syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations and diagnosis of obesity hypoventilation syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Amanda Piper, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brendon Yee, MBChB, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            M Safwan Badr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 18, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obesity hypoventilation syndrome (OHS) is defined as the presence of
         <strong>
          awake
         </strong>
         alveolar hypoventilation in an obese individual which cannot be attributed to other conditions associated with alveolar hypoventilation [
         <a href="#rid1">
          1-3
         </a>
         ]. OHS is associated with increased cardiovascular morbidity and mortality. Consequently, early detection and treatment are crucial to minimize these adverse effects.
        </p>
        <p>
         The clinical manifestations, diagnosis, and complications of OHS are reviewed here, while the pathogenesis and treatment are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7697.html" rel="external">
          "Epidemiology and pathogenesis of obesity hypoventilation syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7713.html" rel="external">
          "Treatment and prognosis of the obesity hypoventilation syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7714.html" rel="external">
          "Noninvasive positive airway pressure therapy for the obesity hypoventilation syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H577185932">
         <span class="h1">
          DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         OHS is defined by raised awake arterial pressure of carbon dioxide levels in patients with obesity in whom alternative causes hypercapnia and hypoventilation have been excluded.
        </p>
        <p class="headingAnchor" id="H1675770575">
         <span class="h1">
          PROPOSED STAGING
         </span>
         <span class="headingEndMark">
          —
         </span>
         However, it is now recognized that nocturnal hypoventilation precedes the development of awake hypercapnia, with earlier recognition and treatment of the problem potentially reducing the development of significant comorbid conditions. Recognizing this, a European Respiratory Society taskforce has proposed a staging schema for hypoventilation in patients with obesity (ie, body mass index &gt;30 kg/m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. Patients with obstructive sleep apnea (OSA) and no hypercapnia were considered stage 0. Stages I and II represented patients with obesity-associated sleep hypoventilation but normal awake arterial pressure of carbon dioxide and either serum bicarbonate &lt;27 mmol/L (stage I) or &gt;27 mmol/L (stage II). Stages III and IV encompassed classically defined OHS patients with or without concurrent OSA. Those in stage IV were distinguished from stage III by the presence of significant cardiometabolic comorbidities.
        </p>
        <p class="headingAnchor" id="H1272507285">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major risk factor for OHS is obesity (body mass index [BMI] ≥30 kg/m
         <sup>
          2
         </sup>
         ), in particular, severe obesity (BMI &gt;50 kg/m
         <sup>
          2
         </sup>
         ), where prevalence may be as high as 50 percent. However, not all patients with obesity develop OHS.
        </p>
        <p>
         Risk factors in obese patients are poorly defined but may include [
         <a href="#rid4">
          4-6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant increase in waist:hip ratio (ie, central obesity)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced lung function due to obesity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced inspiratory muscle strength
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe obstructive sleep apnea (OSA; eg, apnea hypopnea index &gt;30 events per hour)
        </p>
        <p>
        </p>
        <p>
         Unlike OSA, male sex is not a risk factor for OHS [
         <a href="#rid7">
          7-9
         </a>
         ]. However, females may present somewhat differently.
        </p>
        <p>
         Patients with OHS usually present in the fifth and sixth decades of life.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations of OHS are nonspecific and reflect the manifestations of obesity, coexistent obstructive sleep apnea (OSA is present in 90 percent of OHS) or of OHS-related complications (eg, pulmonary hypertension).
        </p>
        <p class="headingAnchor" id="H717782162">
         <span class="h2">
          Symptoms and signs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with OHS are obese (body mass index [BMI] ≥30 kg/m
         <sup>
          2
         </sup>
         ), hypersomnolent individuals. Ninety percent have at least some coexisting OSA (apnea hypopnea index [AHI] &gt;5 events per hour), with severe OSA (eg, AHI &gt;30 events per hour) seen in 70 percent of patients [
         <a href="#rid10">
          10
         </a>
         ] (eg, daytime hypersomnolence, loud snoring, choking during sleep, resuscitative snorting, fatigue, impaired concentration and memory, a small oropharynx, and a thick neck) [
         <a href="#rid1">
          1,11
         </a>
         ].
        </p>
        <p>
         The 10 percent of individuals with OHS who have coexistent sleep hypoventilation without significant OSA present similarly to those with the OHS-OSA phenotype, except witnessed apneas during sleep are less common [
         <a href="#rid11">
          11
         </a>
         ]. They are also more likely to be older females [
         <a href="#rid12">
          12,13
         </a>
         ]. However, standard history taking and questionnaires do not readily establish or exclude an OHS diagnosis [
         <a href="#rid14">
          14
         </a>
         ]. The manifestations of OSA and nocturnal hypoventilation are provided in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7701.html" rel="external">
          "Central sleep apnea: Risk factors, clinical presentation, and diagnosis", section on 'Clinical findings'
         </a>
         .)
        </p>
        <p>
         Many patients with OHS present late in the course of their disease and have manifestations of end-stage disease including the following [
         <a href="#rid1">
          1,6,15-17
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe hypoxemic hypercapnic respiratory failure – While many patients present with chronic stable symptoms or chronic hypercapnic respiratory failure, about one-third of patients present with acute-on-chronic respiratory failure prompting hospital admission [
         <a href="#rid15">
          15,17-21
         </a>
         ]. There is some evidence to suggest that females may present later than males and are more likely to present with acute-on-chronic respiratory failure [
         <a href="#rid19">
          19,22
         </a>
         ]. Such patients are often misdiagnosed as having chronic obstructive pulmonary disease or asthma, despite an absence of obstruction on pulmonary function testing [
         <a href="#rid23">
          23
         </a>
         ]. Daytime hypoxemia and significant and sustained reductions in overnight oximetry (eg, peripheral saturation &lt;80 percent) are features that are uncommon in OSA or obesity alone [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1612.html" rel="external">
          "Pulse oximetry"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7694.html" rel="external">
          "Home sleep apnea testing for obstructive sleep apnea in adults", section on 'Pulse oximetry'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Right heart failure from pulmonary hypertension (dyspnea on exertion, elevated jugular venous pressure, hepatomegaly, and pedal edema) and less commonly, facial plethora from polycythemia.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3849343672">
         <span class="h2">
          Laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         OHS may be associated with the following findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Elevated serum bicarbonate (&gt;27 mEq/L)
         </strong>
         – Almost all patients with OHS have an elevated serum bicarbonate (venous and/or arterial), which is usually a clue that the patient is chronically hypercapnic. However, it is nonspecific since other etiologies can raise the bicarbonate level (eg, dehydration, medications) and it is not 100 percent sensitive since other conditions (eg, lactic acidosis, chronic hyperventilation) may lower the bicarbonate level.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This cut-off is based upon limited data. One observational study reported that a venous serum bicarbonate of &gt;27 mEq/L had a 92 percent sensitivity for identifying awake hypercapnia in obese individuals, although specificity was significantly lower (50 percent) [
         <a href="#rid25">
          25
         </a>
         ]. A bicarbonate level &lt;27 mEq/L had 97 percent negative predictive value for excluding the diagnosis in this study. Another study reported a sensitivity of 85 percent and specificity of 89 percent in patients with levels &gt;27 mEq/L when capillary blood gas samples were used [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypercapnia (arterial pressure of carbon dioxide [PaCO
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          ] ≥45 mmHg)
         </strong>
         – Consistent with the phenomenon of hypoventilation, all patients with OHS have hypercapnia on arterial blood gas analysis when awake and on room air. Although most patients with OHS present with chronic elevations in the PaCO
         <sub>
          2
         </sub>
         , about one-third have acute-on-chronic respiratory failure [
         <a href="#rid17">
          17,20,21
         </a>
         ]. A raised bicarbonate (&gt;27 mmol/L) or base excess (&gt;3 mmol/L) in the absence of another cause for a metabolic alkalosis in an obese individual with a PaCO
         <sub>
          2
         </sub>
         &lt;45 mmHg may be an early indicator of OHS, warranting closer investigation [
         <a href="#rid27">
          27,28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1648.html" rel="external">
          "Arterial blood gases"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16991.html" rel="external">
          "Venous blood gases and other alternatives to arterial blood gases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypoxemia (partial pressure of oxygen &lt;70 mmHg)
         </strong>
         – Hypoxemia is usually present. The calculated alveolar-arterial (A-a) oxygen gradient is classically normal, although a mild widening is not unusual related to ventilation-perfusion mismatching or coexistent parenchymal or vascular lung disease [
         <a href="#rid29">
          29,30
         </a>
         ]. Severe nocturnal desaturation is also common (eg, peripheral saturation &lt;80 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Polycythemia
         </strong>
         — Polycythemia due to recurrent hypoventilation- or OSA-associated hypoxemia is uncommon but may be present as a late manifestation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3017787536">
         <span class="h2">
          Pulmonary function tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although findings of restriction are more commonly seen in obese patients with OHS than in eucapnic obese patients, they are nonspecific, and normal pulmonary function tests (PFTs) do not exclude the diagnosis. In general, PFTs are more useful for ruling out underlying causes of hypoventilation. (See
         <a class="local">
          'Exclude other causes of hypercapnia and alveolar hypoventilation'
         </a>
         below.)
        </p>
        <p>
         In OHS a restrictive pattern on PFTs due to obesity is common, particularly in those with a higher BMI (eg, BMI &gt;50 kg/m
         <sup>
          2
         </sup>
         ); both forced vital capacity (FVC) and forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) are reduced, while the FEV
         <sub>
          1
         </sub>
         /FVC ratio is preserved [
         <a href="#rid31">
          31,32
         </a>
         ]. More commonly, a reduction in functional residual capacity and expiratory reserve volume is seen [
         <a href="#rid32">
          32
         </a>
         ]. FVC values were found in one study to be lower in patients with OHS than OSA but the threshold was ill-defined [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4320.html" rel="external">
          "Chest wall diseases and restrictive physiology"
         </a>
         .)
        </p>
        <p>
         Severe restriction is uncommon with obesity and may indicate another restrictive lung disorder.
        </p>
        <p class="headingAnchor" id="H3068127586">
         <span class="h2">
          Imaging and cardiac studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         In OHS, typical findings on chest radiograph include elevation of both hemidiaphragms due to the obese abdomen and the heart may be enlarged due to right ventricular hypertrophy or pericardial fat.
        </p>
        <p>
         Evidence of right ventricle enlargement from pulmonary hypertension that complicates advanced OHS may be seen on electrocardiography (EKG) and echocardiography [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1711376288">
         <span class="h1">
          DIAGNOSTIC APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnostic approach focuses on establishing awake (often daytime) hypoventilation in an obese patient in the absence of other causes of alveolar hypoventilation. Polysomnography with continuous nocturnal carbon dioxide (CO
         <sub>
          2
         </sub>
         ) monitoring is the gold standard for the evaluation of patients suspected of having OHS. Testing should be performed to characterize the type of underlying sleep disordered breathing (SDB; ie, OHS with or without coexisting obstructive sleep apnea [OSA]). (See
         <a class="local">
          'Identify coexistent sleep disordered breathing'
         </a>
         below.)
        </p>
        <p>
         For patients who present with acute-on-chronic hypercapnic respiratory failure suspected to be due to OHS, immediate treatment with positive pressure therapy is appropriate to stabilize their clinical condition [
         <a href="#rid17">
          17,19,21
         </a>
         ]. Once the patient has improved and is stable, a diagnostic evaluation can be initiated. The treatment of OHS is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7713.html" rel="external">
          "Treatment and prognosis of the obesity hypoventilation syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7714.html" rel="external">
          "Noninvasive positive airway pressure therapy for the obesity hypoventilation syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2500227368">
         <span class="h2">
          Suspecting obesity hypoventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A strong clinical suspicion for OHS is critical for the diagnosis. We typically initiate evaluation in obese patients (body mass index [BMI] ≥30 kg/m
         <sup>
          2
         </sup>
         ) with suspected or known OSA (or SDB), particularly those with severe OSA (eg, apnea hypopnea index &gt;60 events per hour) since the prevalence is high in this population.
        </p>
        <p>
         We also initiate evaluation in obese individuals with or without OSA who have the following clinical features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unexplained awake room air peripheral saturation (SpO
         <sub>
          2
         </sub>
         ) ≤94 percent or an overnight nadir saturation &lt;80 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unexplained dyspnea on exertion
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms and signs of pulmonary hypertension and/or right-sided heart failure (eg, elevated jugular venous pressure, hepatomegaly, and pedal edema)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Facial plethora, which may indicate polycythemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A raised bicarbonate on venous blood sampling (see
         <a class="local">
          'Laboratory tests'
         </a>
         above)
        </p>
        <p>
        </p>
        <p>
         Many of these features are more common in patients with OHS than in eucapnic obese individuals or in patients who have OSA alone [
         <a href="#rid1">
          1,4,6,15-17,24,25,35
         </a>
         ].
        </p>
        <p>
         Hypoventilation first becomes apparent during sleep in patients with obesity [
         <a href="#rid2">
          2
         </a>
         ]. In one study, the prevalence of obesity-related sleep hypoventilation (ORSH) had a prevalence of 19 percent among 94 obese patients (BMI &gt;40 kg/m
         <sup>
          -2
         </sup>
         ). These individuals experienced a rise in CO
         <sub>
          2
         </sub>
         during sleep with a normal or raised bicarbonate during wakefulness while arterial pressure of CO
         <sub>
          2
         </sub>
         (PaCO
         <sub>
          2
         </sub>
         ) remained &lt;45 mmHg [
         <a href="#rid2">
          2
         </a>
         ]. Predictors of ORSH were awake oxygen saturation ≤93 percent and a partial PaCO
         <sub>
          2
         </sub>
         of ≥45 mmHg in the supine position [
         <a href="#rid36">
          36
         </a>
         ]. These findings have led some experts to suggest that ORSH is a precursor to OHS. However, further studies are needed to confirm the evolution of ORSH to OHS.
        </p>
        <p>
         Further details regarding the clinical manifestations of OHS are discussed above. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3343178309">
         <span class="h2">
          Indicators of chronic alveolar hypoventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients in whom OHS is suspected, the presence of chronic hypoventilation is usually inferred when a chronic respiratory acidosis (hypercapnic respiratory acidosis) on arterial blood gas analysis (ABG) is demonstrated together with compensatory metabolic alkalosis (ie, elevated bicarbonate).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ABG – Whether an ABG should be obtained in all patients suspected of having OHS has been the subject of debate. We and others suggest that when the suspicion for OHS is strong, an ABG should be measured. ABGs should be performed while the patient is awake, sitting upright, and breathing room air (so that alveolar-arterial [A-a] oxygen gradient can be calculated). Where ABGs are difficult to obtain, venous blood sampling can be used as a surrogate for pH, PCO
         <sub>
          2
         </sub>
         , and bicarbonate [
         <a href="#rid37">
          37,38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1648.html" rel="external">
          "Arterial blood gases"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16991.html" rel="external">
          "Venous blood gases and other alternatives to arterial blood gases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum bicarbonate – For those in whom the suspicion is low to moderate (eg, &lt;20 percent), obtaining serum bicarbonate is typically sufficient. Based upon the results we suggest the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bicarbonate level &gt;27 mEq/L – An elevated bicarbonate level &gt;27 mEq/L significantly increases the likelihood of OHS, and an ABG should be done to investigate for the presence of chronic hypercapnic acidosis (PaCO
         <sub>
          2
         </sub>
         ≥45 mmHg). ABGs can also identify hypoxemia. Should chronic respiratory acidosis with compensatory metabolic alkalosis be identified, then OHS is likely and if not identified, then OHS is unlikely. Interpretation of acid-base disturbances and distinguishing acute, acute-on-chronic, and chronic hypercapnia  (
         <a class="graphic graphic_figure graphicRef79833" href="/z/d/graphic/79833.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef58687" href="/z/d/graphic/58687.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_figure graphicRef63315" href="/z/d/graphic/63315.html" rel="external">
          figure 3
         </a>
         ) are discussed separately (See
         <a class="medical medical_review" href="/z/d/html/1458.html" rel="external">
          "The evaluation, diagnosis, and treatment of the adult patient with acute hypercapnic respiratory failure", section on 'Arterial blood gas analysis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2352.html" rel="external">
          "Simple and mixed acid-base disorders", section on 'Respiratory acid-base disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bicarbonate level is ≤27 mEq/L – If the bicarbonate level is ≤27 mEq/L, OHS is unlikely, particularly when the suspicion for OHS is low to moderate. An ABG is not absolutely necessary in this population. However, the approach in this population should be individualized. An ABG may be considered in obese patients with borderline elevations in bicarbonate, reduced oxygenation parameters, and suspected complex acid-base disturbance (eg, acute-on-chronic hypercapnia, triple acid-base disturbance), as well as in those in whom an ABG would facilitate excluding an alternate diagnosis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H850608177">
         <span class="h2">
          Exclude other causes of hypercapnia and alveolar hypoventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For those in whom a chronic respiratory acidosis with compensatory metabolic alkalosis is found, additional testing is necessary to exclude other diseases that can cause or contribute to chronic alveolar hypoventilation or hypercapnia. Disorders that commonly coexist with obesity that may contribute to hypercapnia include chronic obstructive pulmonary disease, restrictive lung disease (eg, neuromuscular weakness, severe interstitial lung disease, chest wall disease), hypothyroidism, electrolyte disturbances, and chronic sedative use [
         <a href="#rid1">
          1,11
         </a>
         ]. Testing should be individualized but generally includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum chemistries and electrolytes
         </strong>
         – Electrolyte disturbances that may exacerbate hypercapnia include hypophosphatemia, hypomagnesemia, and rarely, hypermagnesemia, hypokalemia, or hypercalcemia. If found, these should be corrected and the ABG repeated. (See
         <a class="medical medical_review" href="/z/d/html/848.html" rel="external">
          "Hypomagnesemia: Clinical manifestations of magnesium depletion"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/847.html" rel="external">
          "Hypophosphatemia: Clinical manifestations of phosphate depletion"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complete blood count
         </strong>
         – Chronic hypoxemia from underlying lung disease may be associated with polycythemia, which may be a useful tool to monitor response to therapy [
         <a href="#rid31">
          31,39
         </a>
         ]. Although rare, an elevated eosinophil fraction on a complete blood count may be consistent with neuropathy from eosinophilic myalgia. (See
         <a class="medical medical_review" href="/z/d/html/7075.html" rel="external">
          "Diagnostic approach to the patient with erythrocytosis/polycythemia", section on 'Causes of absolute polycythemia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">
          "Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thyroid function tests
         </strong>
         – Hypothyroidism may contribute to the chronic ventilatory failure of OHS by decreasing chemo-responsiveness, causing OSA (due to macroglossia and/or upper airway dilator muscle dysfunction), or causing either a myopathy or neuropathy that affects the respiratory muscles [
         <a href="#rid40">
          40-43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7891.html" rel="external">
          "Laboratory assessment of thyroid function"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/848.html" rel="external">
          "Hypomagnesemia: Clinical manifestations of magnesium depletion"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/847.html" rel="external">
          "Hypophosphatemia: Clinical manifestations of phosphate depletion"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary function tests
         </strong>
         – Pulmonary function tests including spirometry, lung volumes, diffusing capacity, and inspiratory and expiratory pressures may facilitate the identification and severity of a potential underlying lung disease and should be performed in the chronic stable state. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6965.html" rel="external">
          "Tests of respiratory muscle strength"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging
         </strong>
         – A chest radiograph should be performed to exclude parenchymal lung disease, chest wall disease, asymmetrical elevation of a hemidiaphragm (ie, diaphragm paralysis), and cardiomegaly.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         – Rarely, a toxicology screen (eg, concomitant benzodiazepine or narcotic use) or creatine phosphokinase (eg, contributing myositis) are obtained.
        </p>
        <p>
        </p>
        <p>
         Further details regarding the evaluation of acute hypercapnia  (
         <a class="graphic graphic_table graphicRef103091" href="/z/d/graphic/103091.html" rel="external">
          table 1
         </a>
         ) are discussed separately (see
         <a class="medical medical_review" href="/z/d/html/1458.html" rel="external">
          "The evaluation, diagnosis, and treatment of the adult patient with acute hypercapnic respiratory failure"
         </a>
         )
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          IDENTIFY COEXISTENT SLEEP DISORDERED BREATHING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ideally, in-laboratory polysomnography (PSG) is performed in all patients suspected as having OHS, in whom a diagnosis of obstructive sleep apnea (OSA) or other sleep disordered breathing (SDB) does
         <strong>
          not
         </strong>
         already exist. However, many factors including third party payor issues, degree of obesity, and likelihood of OSA or sleep-hypoventilation determine what sleep test is chosen.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Factors favoring in-laboratory PSG include morbid obesity (body mass index [BMI] &gt;40 kg/m
         <sup>
          2
         </sup>
         ), high likelihood of sleep-related hypoventilation (as carbon dioxide [CO
         <sub>
          2
         </sub>
         ] monitoring is available only with in-center testing), heart failure, and significant daytime or nocturnal hypoxemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Home sleep apnea testing (HSAT) is not ideal for rule out OHS as HSAT is best suited for uncomplicated, high probability obstructive sleep apnea cases. It should be noted that HSAT does not detect sleep-related hypoventilation, thus necessitating PSG with continuous nocturnal CO
         <sub>
          2
         </sub>
         monitoring. HSAT may be suitable in those with nonmorbid obesity (BMI 30 to 40 kg/m
         <sup>
          2
         </sup>
         ) in whom the likelihood of OSA is high or those in whom the issue of cost expressly prohibits PSG evaluation.
        </p>
        <p>
        </p>
        <p>
         Although PSG or HSAT is not required to diagnose OHS, sleep testing distinguishes the 90 percent of patients with OHS who have coexistent OSA from the 10 percent of patients who have sleep-related hypoventilation alone [
         <a href="#rid11">
          11,44
         </a>
         ]. Determining the type of SDB is important since it has implications for the type of therapy administered. Further details regarding diagnostic testing are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Diagnostic tests'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7694.html" rel="external">
          "Home sleep apnea testing for obstructive sleep apnea in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7701.html" rel="external">
          "Central sleep apnea: Risk factors, clinical presentation, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Although, the apnea hypopnea index [AHI] is likely to be higher in OHS patients than those with eucapnic OSA, it does not distinguish these groups [
         <a href="#rid25">
          25,45
         </a>
         ]. However, patients with OHS tend to have severe OSA (eg, AHI &gt;50/hour) [
         <a href="#rid25">
          25,45,46
         </a>
         ] and usually have more profound oxygen desaturation during sleep than patients with OSA alone, spending a significantly larger part of sleep time with saturations &lt;90 percent [
         <a href="#rid45">
          45,47,48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/99553.html" rel="external">
          "Polysomnography in the evaluation of sleep-disordered breathing in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3208359793">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         OHS is a diagnosis of exclusion that can be made when the following criteria are met [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obesity (body mass index [BMI] ≥30 kg/m
         <sup>
          2
         </sup>
         ; ≥95
         <sup>
          th
         </sup>
         percentile for age and sex for children)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypoventilation during wakefulness as indicated by a partial pressure of carbon dioxide (PCO
         <sub>
          2
         </sub>
         ) ≥45 mmHg as measured by arterial PCO
         <sub>
          2
         </sub>
         (PaCO
         <sub>
          2
         </sub>
         ), end-tidal PCO
         <sub>
          2
         </sub>
         (P
         <sub>
          et
         </sub>
         CO
         <sub>
          2
         </sub>
         ), or transcutaneous PCO
         <sub>
          2
         </sub>
         (P
         <sub>
          tc
         </sub>
         CO
         <sub>
          2
         </sub>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypoventilation is not primarily due to lung parenchymal or airway disease, chest wall disorder (other than mass loading from obesity), medication use, neurologic disorder, muscle weakness, or a known congenital or idiopathic central alveolar hypoventilation syndrome (see
         <a class="local">
          'Exclude other causes of hypercapnia and alveolar hypoventilation'
         </a>
         above)
        </p>
        <p>
        </p>
        <p>
         Although the majority also have sleep-disordered breathing (nocturnal obstructive and nonobstructive events), it is the awake (ie, typically daytime) hypoventilation that is critical for diagnosis.
        </p>
        <p>
         The absence of an alternative cause of hypercapnic hypoventilation is an important requirement for the diagnosis of OHS. In clinical practice, patients frequently have additional diseases that cause acute and/or chronic hypercapnia. However, assessing the contributions of additional etiologies may be tricky and a matter of clinical judgement. If a potential contributing etiology is mild or considered unlikely to cause hypercapnia, then it is appropriate to diagnose OHS. In contrast, if a coexisting disease is severe and considered likely contributing to hypercapnia, OHS cannot be diagnosed with certainty. (See
         <a class="local">
          'Exclude other causes of hypercapnia and alveolar hypoventilation'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         Because symptoms are nonspecific, the diagnosis of OHS is frequently delayed. It is commonly misdiagnosed as asthma or chronic obstructive pulmonary disease [
         <a href="#rid23">
          23
         </a>
         ] and some patients are not diagnosed until hospitalization for acute-on-chronic respiratory failure occurs. (See
         <a class="local">
          'Symptoms and signs'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2047860715">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main competing diagnosis for the symptoms of OHS is obstructive sleep apnea (OSA). Apart from the presence of chronic respiratory acidosis with compensatory metabolic alkalosis, both disorders are often clinically indistinguishable from one another. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         Common etiologies for respiratory hypercapnia and alveolar hypoventilation are typically distinguished by history, examination, pulmonary function testing, imaging, and laboratory findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic obstructive pulmonary disease (COPD) – COPD may be identified in those with a smoking history, obstruction on pulmonary function tests, and imaging findings of emphysema. (See
         <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">
          "Chronic obstructive pulmonary disease: Diagnosis and staging"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Interstitial lung diseases (ILD) – ILD may be identified in those with imaging findings of parenchymal abnormalities and restriction on pulmonary function tests. (See
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neuromuscular (NM) disorders – NM disorders may be identified by history (eg, weak cough), weakness on examination, and restrictive deficit and muscle weakness on lung function testing. Chest imaging may reveal an elevated hemidiaphragm to suggest diaphragmatic paralysis. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest wall disorders – Such disorders (eg, kyphoscoliosis) may be obvious on clinical examination or on imaging. (See
         <a class="medical medical_review" href="/z/d/html/4320.html" rel="external">
          "Chest wall diseases and restrictive physiology"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypothyroidism – Hypothyroidism is typically evident on laboratory testing. (See
         <a class="medical medical_review" href="/z/d/html/7846.html" rel="external">
          "Clinical manifestations of hypothyroidism"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">
          "Diagnosis of and screening for hypothyroidism in nonpregnant adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic sedative use – Use of sedatives may be found on history or toxicology testing. (See
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1890609042">
         <span class="h1">
          ASSESS COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with OHS should be assessed for common complications, many of which are shared with obesity alone  (
         <a class="graphic graphic_table graphicRef94511" href="/z/d/graphic/94511.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid49">
          49
         </a>
         ]. These are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">
          "Overweight and obesity in adults: Health consequences"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7713.html" rel="external">
          "Treatment and prognosis of the obesity hypoventilation syndrome", section on 'Treatment of comorbid conditions'
         </a>
         .)
        </p>
        <p>
         Specifically, patients with OHS should be assessed for the following common complications:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild to moderate pulmonary hypertension (PH) – Up to two-thirds of patients with OHS have PH. Thus, at diagnosis we typically perform an electrocardiogram and echocardiogram in this population to evaluate for PH, the details of which are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8262.html" rel="external">
          "Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiovascular and metabolic comorbidities – Conditions such as hypertension, congestive heart failure, and insulin resistance are all more common in patients with OHS than in patients with eucapnic obesity, and may be present three or more years prior to the diagnosis of OHS [
         <a href="#rid4">
          4,49-51
         </a>
         ]. Thus, at the time of diagnosis we typically perform fasting bloods assessing plasma glucose, triglycerides, and cholesterol to ensure comorbid conditions have been identified and are being appropriately managed. A cross sectional study of stable OHS patients found cardiovascular morbidity risk was significantly higher in those with the predominantly sleep hypoventilation OHS phenotype despite these individuals exhibiting less severe nocturnal and awake gas exchange compared with those who had OHS and significant OSA [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The natural history and prognosis of OHS is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7713.html" rel="external">
          "Treatment and prognosis of the obesity hypoventilation syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7910704">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Obesity hypoventilation syndrome (OHS) is defined as the presence of awake alveolar hypoventilation (arterial pressure of carbon dioxide [PaCO
         <sub>
          2
         </sub>
         ] ≥45 mmHg) in an obese individual (body mass index [BMI] ≥30 kg/m
         <sup>
          2
         </sup>
         ), which cannot be attributed to other conditions associated with hypoventilation. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Definition'
         </a>
         above and
         <a class="local">
          'Proposed staging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – The symptoms and clinical manifestations of OHS are nonspecific and are more reflective of the manifestations of obesity, coexistent obstructive sleep apnea (OSA; eg, hypersomnolence, snoring, witnessed apneas), or OHS-related complications (eg, pulmonary hypertension). Sleep-related desaturation and daytime hypoxemia are common. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – Our diagnostic approach is the following (see
         <a class="local">
          'Diagnostic approach'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those in whom OHS is strongly suspected (eg, morbidly obese patients with suspected or known OSA), we suggest that an arterial blood gas (ABG) be obtained to look for evidence of alveolar hypoventilation (ie, PaCO
         <sub>
          2
         </sub>
         ≥45 mmHg).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those in whom the suspicion is low to moderate (eg, &lt;20 percent), obtaining serum bicarbonate is typically sufficient; an elevated bicarbonate level &gt;27 mEq/L, increases the likelihood of OHS and should prompt an ABG while a bicarbonate level ≤27 mEq/L suggests that OHS is unlikely, and unless an alternate etiology or complex acid-base disturbance is suspected, an ABG is not usually indicated.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those in whom a chronic respiratory acidosis (PaCO
         <sub>
          2
         </sub>
         ≥45 mmHg) with compensatory metabolic alkalosis is found, additional testing is necessary to exclude other diseases that can cause or contribute to chronic alveolar hypoventilation or hypercapnia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Identify coexistent breathing disorders
         </strong>
         – For those with suspected OHS in whom a diagnosis of OSA does not already exist, in-laboratory polysomnography should ideally be performed based upon the rationale that 90 percent of patients with OHS have coexistent OSA of at least mild to moderate severity while the remainder have sleep-related hypoventilation only. Home sleep apnea testing may be a suitable alternative in those who do not have morbid obesity (ie, BMI 30 to 40 kg/m
         <sup>
          2
         </sup>
         ) in whom the likelihood of OSA is high or those in whom cost is an issue. (See
         <a class="local">
          'Identify coexistent sleep disordered breathing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – OHS is a diagnosis of exclusion (obesity and awake alveolar hypoventilation which cannot be attributed to other conditions associated with hypoventilation). Once diagnosed, all patients with OHS should be assessed for common complications, including pulmonary hypertension and cardiovascular disorders  (
         <a class="graphic graphic_table graphicRef94511" href="/z/d/graphic/94511.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         above and
         <a class="local">
          'Assess complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6259511">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Paul Suratt, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Mokhlesi B. Obesity hypoventilation syndrome: a state-of-the-art review. Respir Care 2010; 55:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Randerath W, Verbraecken J, Andreas S, et al. Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep. Eur Respir J 2017; 49.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed, text revision, American Academy of Sleep Medicine, 2023.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basoglu OK, Tasbakan MS. Comparison of clinical characteristics in patients with obesity hypoventilation syndrome and obese obstructive sleep apnea syndrome: a case-control study. Clin Respir J 2014; 8:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piper AJ, Grunstein RR. Obesity hypoventilation syndrome: mechanisms and management. Am J Respir Crit Care Med 2011; 183:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mokhlesi B, Kryger MH, Grunstein RR. Assessment and management of patients with obesity hypoventilation syndrome. Proc Am Thorac Soc 2008; 5:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castro-Añón O, Pérez de Llano LA, De la Fuente Sánchez S, et al. Obesity-hypoventilation syndrome: increased risk of death over sleep apnea syndrome. PLoS One 2015; 10:e0117808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harada Y, Chihara Y, Azuma M, et al. Obesity hypoventilation syndrome in Japan and independent determinants of arterial carbon dioxide levels. Respirology 2014; 19:1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BaHammam AS. Prevalence, clinical characteristics, and predictors of obesity hypoventilation syndrome in a large sample of Saudi patients with obstructive sleep apnea. Saudi Med J 2015; 36:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masa JF, Corral J, Alonso ML, et al. Efficacy of Different Treatment Alternatives for Obesity Hypoventilation Syndrome. Pickwick Study. Am J Respir Crit Care Med 2015; 192:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olson AL, Zwillich C. The obesity hypoventilation syndrome. Am J Med 2005; 118:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masa JF, Corral J, Caballero C, et al. Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea. Thorax 2016; 71:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BaHammam AS, Pandi-Perumal SR, Piper A, et al. Gender differences in patients with obesity hypoventilation syndrome. J Sleep Res 2016; 25:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tran K, Wang L, Gharaibeh S, et al. Elucidating Predictors of Obesity Hypoventilation Syndrome in a Large Bariatric Surgery Cohort. Ann Am Thorac Soc 2020; 17:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nowbar S, Burkart KM, Gonzales R, et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med 2004; 116:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Povitz M, James MT, Pendharkar SR, et al. Prevalence of Sleep-disordered Breathing in Obese Patients with Chronic Hypoxemia. A Cross-Sectional Study. Ann Am Thorac Soc 2015; 12:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez de Llano LA, Golpe R, Ortiz Piquer M, et al. Short-term and long-term effects of nasal intermittent positive pressure ventilation in patients with obesity-hypoventilation syndrome. Chest 2005; 128:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessler R, Chaouat A, Schinkewitch P, et al. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. Chest 2001; 120:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrillo A, Ferrer M, Gonzalez-Diaz G, et al. Noninvasive ventilation in acute hypercapnic respiratory failure caused by obesity hypoventilation syndrome and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borel JC, Burel B, Tamisier R, et al. Comorbidities and mortality in hypercapnic obese under domiciliary noninvasive ventilation. PLoS One 2013; 8:e52006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Priou P, Hamel JF, Person C, et al. Long-term outcome of noninvasive positive pressure ventilation for obesity hypoventilation syndrome. Chest 2010; 138:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palm A, Midgren B, Janson C, Lindberg E. Gender differences in patients starting long-term home mechanical ventilation due to obesity hypoventilation syndrome. Respir Med 2016; 110:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marik PE, Desai H. Characteristics of patients with the "malignant obesity hypoventilation syndrome" admitted to an ICU. J Intensive Care Med 2013; 28:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bingol Z, Pıhtılı A, Cagatay P, et al. Clinical predictors of obesity hypoventilation syndrome in obese subjects with obstructive sleep apnea. Respir Care 2015; 60:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mokhlesi B, Tulaimat A, Faibussowitsch I, et al. Obesity hypoventilation syndrome: prevalence and predictors in patients with obstructive sleep apnea. Sleep Breath 2007; 11:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macavei VM, Spurling KJ, Loft J, Makker HK. Diagnostic predictors of obesity-hypoventilation syndrome in patients suspected of having sleep disordered breathing. J Clin Sleep Med 2013; 9:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manuel AR, Hart N, Stradling JR. Is a raised bicarbonate, without hypercapnia, part of the physiologic spectrum of obesity-related hypoventilation? Chest 2015; 147:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hart N, Mandal S, Manuel A, et al. Obesity hypoventilation syndrome: does the current definition need revisiting? Thorax 2014; 69:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Littleton SW. Impact of obesity on respiratory function. Respirology 2012; 17:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen J, Rasmussen JP, Eriksen J. Pulmonary function in obese patients scheduled for jejuno-ileostomy. Acta Anaesthesiol Scand 1977; 21:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinemann F, Budweiser S, Dobroschke J, Pfeifer M. Non-invasive positive pressure ventilation improves lung volumes in the obesity hypoventilation syndrome. Respir Med 2007; 101:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piper AJ. Obesity hypoventilation syndrome--the big and the breathless. Sleep Med Rev 2011; 15:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castro-Añón O, Golpe R, Pérez-de-Llano LA, et al. Haemodynamic effects of non-invasive ventilation in patients with obesity-hypoventilation syndrome. Respirology 2012; 17:1269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kauppert CA, Dvorak I, Kollert F, et al. Pulmonary hypertension in obesity-hypoventilation syndrome. Respir Med 2013; 107:2061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandal S, Suh ES, Boleat E, et al. A cohort study to identify simple clinical tests for chronic respiratory failure in obese patients with sleep-disordered breathing. BMJ Open Respir Res 2014; 1:e000022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sivam S, Yee B, Wong K, et al. Obesity Hypoventilation Syndrome: Early Detection of Nocturnal-Only Hypercapnia in an Obese Population. J Clin Sleep Med 2018; 14:1477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mokhlesi B, Masa JF, Brozek JL, et al. Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2019; 200:e6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollier CA, Maxwell LJ, Harmer AR, et al. Validity of arterialised-venous P CO2, pH and bicarbonate in obesity hypoventilation syndrome. Respir Physiol Neurobiol 2013; 188:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Budweiser S, Riedl SG, Jörres RA, et al. Mortality and prognostic factors in patients with obesity-hypoventilation syndrome undergoing noninvasive ventilation. J Intern Med 2007; 261:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez FJ, Bermudez-Gomez M, Celli BR. Hypothyroidism. A reversible cause of diaphragmatic dysfunction. Chest 1989; 96:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ladenson PW, Goldenheim PD, Ridgway EC. Prediction and reversal of blunted ventilatory responsiveness in patients with hypothyroidism. Am J Med 1988; 84:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MASSUMI RA, WINNACKER JL. SEVERE DEPRESSION OF THE RESPIRATORY CENTER IN MYXEDEMA. Am J Med 1964; 36:876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skatrud J, Iber C, Ewart R, et al. Disordered breathing during sleep in hypothyroidism. Am Rev Respir Dis 1981; 124:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessler R, Chaouat A, Weitzenblum E, et al. Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences. Eur Respir J 1996; 9:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaw R, Hernandez AV, Walker E, et al. Determinants of hypercapnia in obese patients with obstructive sleep apnea: a systematic review and metaanalysis of cohort studies. Chest 2009; 136:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Littleton SW, Mokhlesi B. The pickwickian syndrome-obesity hypoventilation syndrome. Clin Chest Med 2009; 30:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banerjee D, Yee BJ, Piper AJ, et al. Obesity hypoventilation syndrome: hypoxemia during continuous positive airway pressure. Chest 2007; 131:1678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Resta O, Foschino-Barbaro MP, Bonfitto P, et al. Prevalence and mechanisms of diurnal hypercapnia in a sample of morbidly obese subjects with obstructive sleep apnoea. Respir Med 2000; 94:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jennum P, Ibsen R, Kjellberg J. Morbidity prior to a diagnosis of sleep-disordered breathing: a controlled national study. J Clin Sleep Med 2013; 9:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg G, Delaive K, Manfreda J, et al. The use of health-care resources in obesity-hypoventilation syndrome. Chest 2001; 120:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borel JC, Roux-Lombard P, Tamisier R, et al. Endothelial dysfunction and specific inflammation in obesity hypoventilation syndrome. PLoS One 2009; 4:e6733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masa JF, Corral J, Romero A, et al. Protective Cardiovascular Effect of Sleep Apnea Severity in Obesity Hypoventilation Syndrome. Chest 2016; 150:68.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7698 Version 37.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20875161" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Obesity hypoventilation syndrome: a state-of-the-art review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27920092" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27920092" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24028180" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Comparison of clinical characteristics in patients with obesity hypoventilation syndrome and obese obstructive sleep apnea syndrome: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21037018" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Obesity hypoventilation syndrome: mechanisms and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18250215" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Assessment and management of patients with obesity hypoventilation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25671545" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Obesity-hypoventilation syndrome: increased risk of death over sleep apnea syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25208458" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Obesity hypoventilation syndrome in Japan and independent determinants of arterial carbon dioxide levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25719582" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Prevalence, clinical characteristics, and predictors of obesity hypoventilation syndrome in a large sample of Saudi patients with obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25915102" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Efficacy of Different Treatment Alternatives for Obesity Hypoventilation Syndrome. Pickwick Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16164877" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The obesity hypoventilation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27406165" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26990045" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Gender differences in patients with obesity hypoventilation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32526148" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Elucidating Predictors of Obesity Hypoventilation Syndrome in a Large Bariatric Surgery Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14706658" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25822569" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Prevalence of Sleep-disordered Breathing in Obese Patients with Chronic Hypoxemia. A Cross-Sectional Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16100142" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Short-term and long-term effects of nasal intermittent positive pressure ventilation in patients with obesity-hypoventilation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11502631" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23103736" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Noninvasive ventilation in acute hypercapnic respiratory failure caused by obesity hypoventilation syndrome and chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23341888" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Comorbidities and mortality in hypercapnic obese under domiciliary noninvasive ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20348200" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Long-term outcome of noninvasive positive pressure ventilation for obesity hypoventilation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26680503" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Gender differences in patients starting long-term home mechanical ventilation due to obesity hypoventilation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22564878" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Characteristics of patients with the "malignant obesity hypoventilation syndrome" admitted to an ICU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25587164" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Clinical predictors of obesity hypoventilation syndrome in obese subjects with obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17187265" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Obesity hypoventilation syndrome: prevalence and predictors in patients with obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23997700" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Diagnostic predictors of obesity-hypoventilation syndrome in patients suspected of having sleep disordered breathing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25080050" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Is a raised bicarbonate, without hypercapnia, part of the physiologic spectrum of obesity-related hypoventilation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23986390" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Obesity hypoventilation syndrome: does the current definition need revisiting?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22040049" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Impact of obesity on respiratory function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/906790" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pulmonary function in obese patients scheduled for jejuno-ileostomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17166707" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Non-invasive positive pressure ventilation improves lung volumes in the obesity hypoventilation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20609602" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Obesity hypoventilation syndrome--the big and the breathless.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22897169" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Haemodynamic effects of non-invasive ventilation in patients with obesity-hypoventilation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24120252" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Pulmonary hypertension in obesity-hypoventilation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25478174" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A cohort study to identify simple clinical tests for chronic respiratory failure in obese patients with sleep-disordered breathing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30176974" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Obesity Hypoventilation Syndrome: Early Detection of Nocturnal-Only Hypercapnia in an Obese Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31368798" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23732508" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Validity of arterialised-venous P CO2, pH and bicarbonate in obesity hypoventilation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17391112" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Mortality and prognostic factors in patients with obesity-hypoventilation syndrome undergoing noninvasive ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2805837" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Hypothyroidism. A reversible cause of diaphragmatic dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3364447" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prediction and reversal of blunted ventilatory responsiveness in patients with hypothyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14162894" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : SEVERE DEPRESSION OF THE RESPIRATORY CENTER IN MYXEDEMA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6792957" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Disordered breathing during sleep in hypothyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8726947" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19567489" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Determinants of hypercapnia in obese patients with obstructive sleep apnea: a systematic review and metaanalysis of cohort studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19700045" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The pickwickian syndrome-obesity hypoventilation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17565018" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Obesity hypoventilation syndrome: hypoxemia during continuous positive airway pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10783935" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Prevalence and mechanisms of diurnal hypercapnia in a sample of morbidly obese subjects with obstructive sleep apnoea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23372461" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Morbidity prior to a diagnosis of sleep-disordered breathing: a controlled national study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11502632" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The use of health-care resources in obesity-hypoventilation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19701463" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Endothelial dysfunction and specific inflammation in obesity hypoventilation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26923627" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Protective Cardiovascular Effect of Sleep Apnea Severity in Obesity Hypoventilation Syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
